Reduced antioxidant defense in early onset first-episode psychosis: A case-control study

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Micó, Juan A ^a   Rojas Corrales, Maria O ^a   Gibert Rahola, Juan ^a   Parellada, Mara ^b   Moreno, Dolores ^b   Fraguas, David ^c   Graell, Montserrat ^d   Gil, Javier ^e   Irazusta, Jon ^e   Castro Fornieles, Josefina ^f   Soutullo, Cesar ^g   Arango, Celso ^b   Otero, Soraya ^h   Navarro, Ana ⁱ   Baeza, Inmaculada ^f   Martínez Cengotitabengoa, Mónica ⁱ   González Pinto, Ana ^e  

^a UNIVERSITY OF CÁDIZ   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^d HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITY OF NAVARRA   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ UNIVERSITY OF CÁDIZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; CATALASE; GLUTATHIONE PEROXIDASE; NEUROLEPTIC AGENT; SUPEROXIDE DISMUTASE; ANTIOXIDANT; GLUTATHIONE; REACTIVE OXYGEN METABOLITE;

ADOLESCENT; ARTICLE; BIPOLAR DISORDER; BLOOD LEVEL; BLOOD SAMPLING; CASE CONTROL STUDY; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EARLY ONSET FIRST EPISODE PSYCHOSIS; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; FOLLOW UP; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SPECTROPHOTOMETRY; BLOOD; COMPARATIVE STUDY; ENZYMOLOGY; METABOLISM; ONSET AGE; PHYSIOLOGY;

ADOLESCENT; AGE OF ONSET; ANTIOXIDANTS; CASE-CONTROL STUDIES; CATALASE; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ERYTHROCYTES; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PSYCHOTIC DISORDERS; REACTIVE OXYGEN SPECIES; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE;

EID: 79851515182     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-26     Document Type: Article

References (67)

1. Cui K, Luo X, Xu K, Ven Murthy MR. Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical antioxidants. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:771-799. 10.1016/j.pnpbp.2004.05.023, 15363603.
2. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000, 12:3721-3728. 10.1046/j.1460-9568.2000.00229.x, 11029642.
3. Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. [Oxidative stress involvement in schizophrenia pathophysiology: a review]. Encephale 2006, 32:244-252. 10.1016/S0013-7006(06)76151-6, 16910626.
4. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996, 19:1-17. 10.1016/0920-9964(95)00049-6, 9147491.
5. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998, 43:674-679. 10.1016/S0006-3223(97)00282-5, 9583001.
6. Yao JK, Reddy RD, van Kammen DP. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 1999, 45:1512-1515. 10.1016/S0006-3223(98)00184-X, 10356635.
7. Andreazza AC, Kauer-Sant'Anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008, 111:135-144. 10.1016/j.jad.2008.04.013, 18539338.
8. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175. 10.1002/cbf.940, 11979513.
9. Michel TM, Thome J, Martin D, Nara K, Zwerina S, Tatschner T, et al. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J Neural Transm 2004, 111:1191-1201. 10.1007/s00702-004-0160-9, 15338334.
10. Reddy R, Sahebarao MP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 1991, 30:409-412. 10.1016/0006-3223(91)90298-Z, 1912133.
11. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 2003, 117:85-88. 10.1016/S0165-1781(02)00303-7, 12581823.
12. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:995-1005. 10.1016/S0278-5846(02)00220-8, 12369276.
13. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003, 69:393-399. 10.1016/j.plefa.2003.08.010, 14623492.
14. Mukerjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996, 19:19-26. 10.1016/0920-9964(95)00048-8, 9147492.
15. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122. 10.1016/S0165-1781(03)00220-8, 14656446.
16. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006, 81:291-300. 10.1016/j.schres.2005.10.011, 16309894.
17. Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001, 6:66-73. 10.1038/sj.mp.4000789, 11244487.
18. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl) 2001, 158:140-145. 10.1007/s002130100860, 11702087.
19. Yao JK, Reddy R, McElhinny LG, van Kammen DP. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998, 32:385-391. 10.1016/S0022-3956(98)00028-4, 9844955.
20. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209. 10.1159/000077368, 15154399.
21. Carmeli E, Bachar A, Barchad S, Morad M, Merrick J. Antioxidant status in the serum of persons with intellectual disability and hypothyroidism: a pilot study. Res Dev Disabil 2008, 29:431-438. 10.1016/j.ridd.2007.08.001, 17869479.
22. Pulido R, Jimenez-Escrig A, Orensanz L, Saura-Calixto F, Jimenez-Escrig A. Study of plasma antioxidant status in Alzheimer's disease. Eur J Neurol 2005, 12:531-535. 10.1111/j.1468-1331.2005.01000.x, 15958093.
23. Ustundag B, Atmaca M, Kirtas O, Selek S, Metin K, Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci 2006, 60:458-464. 10.1111/j.1440-1819.2006.01532.x, 16884448.
24. Golse B, Debray-Ritzen P, Puget K, Michelson AM. Analysis of platelet superoxide dismutase 1 in the development of childhood psychoses. Nouv Presse Med 1977, 6:2449.
25. Golse B, Debray-Ritzen P, Puget K, Michelson AM. Erythrocyte and platelet levels of superoxide dismutase (1 and 2) and glutathione peroxidase in developmental child psychoses. Nouv Presse Med 1978, 7:1952.
26. Golse B, Debray-Ritzen P, Durosay P, Puget K, Michelson AM. Alterations in two enzymtes: superoxide dismutase and glutathione peroxidase in developmental infantile psychosis (infantile autism). Rev Neurol (Paris) 1978, 134:699-705.
27. Asarnow JR, Tompson MC, McGrath EP. Annotation: childhood-onset schizophrenia: clinical and treatment issues. J Child Psychol Psychiatry 2004, 45:180-194. 10.1111/j.1469-7610.2004.00213.x, 14982235.
28. Ballageer T, Malla A, Manchanda R, Takhar J, Haricharan R. Is adolescent-onset first-episode psychosis different from adult onset?. J Am Acad Child Adolesc Psychiatry 2005, 44:782-789. 10.1097/01.chi.0000164591.55942.ea, 16034280.
29. American Psychiatric Association DSM-IV. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association.
30. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997, 36:980-988. 10.1097/00004583-199707000-00021, 9204677.
31. Ulloa RE, Ortiz S, Higuera F, Nogales I, Fresan A, Apiquian R, et al. Interrater reliability of the Spanish version of Schedule for Affective Disorders and Schizophrenia for School-Age Children--Present and Lifetime version (K-SADS-PL). Actas Esp Psiquiatr 2006, 34:36-40.
32. Castro-Fornieles J, Parellada M, Gonzalez-Pinto A, Moreno D, Graell M, Baeza I, et al. The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. Schizophr Res 2007, 91:226-237. 10.1016/j.schres.2006.12.004, 17267179.
33. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 1999, 26:1231-1237. 10.1016/S0891-5849(98)00315-3, 10381194.
34. Nourooz-Zadeh J, Tajaddini-Sarmadi J, Wolff SP. Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal Biochem 1994, 220:403-409. 10.1006/abio.1994.1357, 7978285.
35. Fossati P, Prencipe L, Berti G. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem 1980, 26:227-231.
36. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967, 70:158-169.
37. Nebot C, Moutet M, Huet P, Xu JZ, Yadan JC, Chaudiere J. Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of a tetracyclic catechol. Anal Biochem 1993, 214:442-451. 10.1006/abio.1993.1521, 8109732.
38. Frey BN, Andreazza AC, Kunz M, Gomes FA, Quevedo J, Salvador M, et al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:283-285. 10.1016/j.pnpbp.2006.06.011, 16859818.
39. Yao JK, Reddy R, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000, 97:137-151. 10.1016/S0165-1781(00)00230-4, 11166086.
40. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V, da S, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007, 421:33-36. 10.1016/j.neulet.2007.05.016, 17548157.
41. Savas HA, Gergerlioglu HS, Armutcu F, Herken H, Yilmaz HR, Kocoglu E, et al. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 2006, 7:51-55. 10.1080/15622970510029993, 16428220.
42. Selek S, Savas HA, Gergerlioglu HS, Bulbul F, Uz E, Yumru M. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2008, 107:89-94. 10.1016/j.jad.2007.08.006, 17869345.
43. Vaiva G, Thomas P, Leroux JM, Cottencin O, Dutoit D, Erb F, et al. Erythrocyte superoxide dismutase (eSOD) determination in positive moments of psychosis. Therapie 1994, 49:343-348.
44. Groner Y, Avraham KB, Schickler M, Yarom R, Knobler H. Clinical symptoms of Down syndrome are manifested in transgenic mice overexpressing the human Cu/Zn-superoxide dismutase gene. Prog Clin Biol Res 1990, 360:233-262.
45. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19:89-95. 10.1097/00004850-200403000-00006, 15076017.
46. Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res 2003, 62:213-224. 10.1016/S0920-9964(02)00405-X, 12837517.
47. Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 2006, 22:83-93.
48. Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 1997, 324(Pt 1):25-28. 1218396, 9164836.
49. Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem 2003, 384:505-516. 10.1515/BC.2003.059, 12751781.
50. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978, 14:633-643.
51. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J Neurochem 2006, 97:1634-1658. 10.1111/j.1471-4159.2006.03907.x, 16805774.
52. Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999, 55:659-665. 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C, 10220107.
53. Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2006, 79:586-592. 10.1086/507566, 1559555, 16909399.
54. Castagne V, Rougemont M, Cuenod M, Do KQ. Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis 2004, 15:93-105. 10.1016/j.nbd.2003.09.005, 14751774.
55. Rabinovic AD, Hastings TG. Role of endogenous glutathione in the oxidation of dopamine. J Neurochem 1998, 71:2071-2078. 10.1046/j.1471-4159.1998.71052071.x, 9798932.
56. Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, et al. gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem 1995, 65:2652-2662. 10.1046/j.1471-4159.1995.65062652.x, 7595563.
57. Cabungcal JH, Nicolas D, Kraftsik R, Cuenod M, Do KQ, Hornung JP. Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia. Neurobiol Dis 2006, 22:624-637. 10.1016/j.nbd.2006.01.003, 16481179.
58. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007, 104:16621-16626. 10.1073/pnas.0706778104, 2034265, 17921251.
59. Andreazza AC, Frey BN, Erdtmann B, Salvador M, Rombaldi F, Santin A, et al. DNA damage in bipolar disorder. Psychiatry Res 2007, 153:27-32. 10.1016/j.psychres.2006.03.025, 17582509.
60. Uno K, Nicholls SJ. Biomarkers of inflammation and oxidative stress in atherosclerosis. Biomark Med 2010, 4:361-373. 10.2217/bmm.10.57, 20550470.
61. Dominguez LJ, Galioto A, Pineo A, Ferlisi A, Ciaccio M, Putignano E, et al. Age, homocysteine, and oxidative stress: relation to hypertension and type 2 diabetes mellitus. J Am Coll Nutr 2010, 29:1-6.
62. Faust F, Kassie F, Knasmuller S, Boedecker RH, Mann M, Mersch-Sundermann V. The use of the alkaline comet assay with lymphocytes in human biomonitoring studies. Mutat Res 2004, 566:209-229. 10.1016/j.mrrev.2003.09.007, 15082238.
63. De HM, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009, 24:412-424. 10.1016/j.eurpsy.2009.01.005, 19682863.
64. Medved V, Jovanovic N, Knapic VP. The comorbidity of diabetes mellitus and psychiatric disorders. Psychiatr Danub 2009, 21:585-588.
65. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11:851-876. 10.1017/S1461145707008401, 18205981.
66. Volkmar FR. Childhood and adolescent psychosis: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996, 35:843-851. 10.1097/00004583-199607000-00009, 8768343.
67. Mahadik SP, Pillai A, Joshi S, Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry 2006, 18:119-131. 10.1080/09540260600581993, 16777666.